Effect of Darbepoetin in Contrast-induced Nephropathy

• Status: Terminated
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the drug that produce red blood cells is effective in the prevention of kidney dysfunction after coronary angiography in patients with chronic kidney disease.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Bundang Hospital
• Collaborator: SMG-SNU Boramae Medical Center
• Treatments: Darbepoetin alfa

Criteria

Inclusion Criteria:

• age over 18 yr

• estimated glomerular filtration rate (GFR) < 60 ml/min/1.73m2

Exclusion Criteria:

• Chronic renal replacement therapy (hemodialysis, peritoneal dialysis, continuous renal replacement therapy)

• Pregnancy or lactation

• Use of contrast agent within 1 week

• Emergent CAG or PCI

• Not recovered from AKI(acute kidney injury)

• Use of nephrotoxic drugs within 48 hr

• Cardiogenic shock (SBP(systolic blood pressure) < 90 mmHg) or pulmonary edema

• Uncontrolled hypertension (SBP ≥ 200 mmHg or DBP(diastolic blood pressure) ≥ 130 mmHg)

• History of hypersensitivity to contrast agent

• Known allergy or hypersensitivity to EPO(erythropoietin)

• Use of EPO within 1 month

• Anemia (hemoglobin < 9 g/dL)

• Ventilatory care